The fourfold number
Twenty-two years of insurance claims, more than 413,000 women with PMOS (PCOS), and a fourfold higher risk of atherosclerotic heart disease that did not go away when researchers adjusted for weight. If you have been told this is a fertility condition, this is the study to bring with you.
Before anything else
A relative risk is not a forecast. Fourfold sounds enormous and it is, but it is fourfold on a baseline that is low for most women in their twenties and thirties — the point of this piece is screening, not alarm. Nothing here is a reason to start or stop a medication. Take it to a clinician.
The renaming was supposed to be the story of the year. In May, after a fourteen-year consensus process involving more than 14,000 patients and clinicians and 56 organizations, polycystic ovary syndrome officially became polyendocrine metabolic ovarian syndrome — PMOS — because the old name pointed at cysts that are not really cysts and hid everything else the condition does.
Two months later, a study arrived that reads like the argument for the new name written out in claims data.
Researchers, including a team at Penn Medicine, pulled US health insurance records from 2000 to 2022 and compared women aged 18 to 50 — more than 413,000 with PMOS, drawn from a pool of roughly 2.5 million. Women with PMOS had about a fourfold higher risk of atherosclerotic cardiovascular disease: the heart attacks and strokes that come from plaque in the arteries. The findings were published in The Lancet Obstetrics, Gynaecology, & Women's Health.
The adjustment that matters
Here is the finding inside the finding. The elevated risk persisted after the researchers accounted for obesity — and for high blood pressure, high cholesterol, and diabetes.
Which means the increase is not simply the downstream consequence of the weight that so often accompanies PMOS. Something else about the condition appears to be contributing. The authors are appropriately cautious about what that something is; the honest answer today is that we don't know, and candidate mechanisms include chronic low-grade inflammation, insulin resistance operating independently of BMI, and androgen effects on the vasculature. Pick your favourite at your own risk.
If the risk survives adjustment for weight, then "lose weight and come back" is not a cardiovascular plan.
We are dwelling on this because of how many women with PMOS have been handed exactly that sentence, for years, as the entirety of their care. This is an observational study built from insurance claims, with all the limits that implies — diagnostic coding is imperfect, and women who get a PMOS code may be women who see doctors more often. But the direction is consistent with a decade of smaller work, and the size is hard to wave away.
What we think it changes
Practically: it strengthens the case that a PMOS diagnosis should come with cardiometabolic screening as a matter of course, early, and not as something you have to request. The study authors point at exactly that — early heart-health screening, plus the ordinary prevention levers of weight management, eating, and movement, started sooner rather than later.
For anyone using this site to choose a provider, it sharpens a question we already ask on your behalf. A platform that will prescribe you a GLP-1 for weight and never look at a lipid panel or a blood pressure reading is not treating PMOS. It is treating a number on a scale that happens to belong to someone with PMOS. Those are different services at similar prices, and the Care Standard exists to tell them apart.
It also sits uncomfortably alongside something we wrote about in One in six: GLP-1 prescribing to women with PMOS has climbed steeply while condition-specific evidence has not kept pace. Cardiovascular risk is one of the places where that gap has real consequences, in both directions — under-treating a metabolic condition is a risk, and treating it without monitoring is also a risk.
Questions worth asking
Given my PMOS, what cardiovascular screening should I be having, and starting at what age? Are we checking lipids and blood pressure at intervals, or only when something feels wrong? If my weight improves, does my cardiovascular risk fully normalize — or does some of it stay? And if I'm on a GLP-1 through a telehealth service, who is tracking those numbers, and where do they go?
That last question is not rhetorical. In a fragmented system the labs get drawn and then live in an inbox nobody owns. Ask who owns yours.
The wider point
The name changed in May because the field decided the condition is polyendocrine and metabolic before it is ovarian. Studies like this one are why. So is the endometriosis and diabetes work we covered in The risk that doesn't stay in the pelvis. Two conditions, filed for decades under reproductive health, both turning out to carry metabolic and cardiovascular weight that the filing obscured.
None of that is comforting exactly. But being told your condition is bigger than you were led to believe is, in our experience, still better than being told it was nothing.
The honest disclaimer. This is general information from the women who write Selene — not medical advice, not a recommendation, and not a prediction about your results. The study described is observational; it shows association, not causation, and relative risk is not the same as your personal risk. No GLP-1 is FDA-approved specifically for PMOS (PCOS), and GLP-1 medications are not a treatment for endometriosis. Selene is editorial: we do not prescribe, sell, or dispense anything.
Sources. Nationwide US cohort on PMOS and atherosclerotic cardiovascular disease, The Lancet Obstetrics, Gynaecology, & Women's Health, July 2026 (reported by Penn Medicine and AJMC); "Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process," The Lancet, 12 May 2026; Endocrine Society announcement on the PMOS name change, 2026.